Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunohistochemical Evaluation of PARP and Caspase-3 as Prognostic Markers in Prostate Carcinomas

Full text
Author(s):
Acar, Vitoria [1] ; Couto Fernandez, Fabio Leite [2] ; Buscariolo, Fabio Fabian [1] ; Novais, Adriana Alonso [3] ; Matheus Pereira, Roseli Aparecida [4] ; Pires de Campos Zuccari, Debora Aparecida [5]
Total Authors: 6
Affiliation:
[1] Sao Jose do Rio Preto Med Sch FAMERP, Sao Jose Do Rio Preto, SP - Brazil
[2] Sao Jose do Rio Preto Med Sch FAMERP, Dept Clin Med, Sao Jose Do Rio Preto, SP - Brazil
[3] Sao Jose do Rio Preto Med Sch FAMERP, Canc Mol Res Lab, Sao Jose Do Rio Preto, SP - Brazil
[4] Sao Jose do Rio Preto Med Sch FAMERP, Dept Nursing, Sao Jose Do Rio Preto, SP - Brazil
[5] Sao Jose do Rio Preto Med Sch FAMERP, Dept Mol Biol, Sao Jose Do Rio Preto, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: CLINICAL MEDICINE & RESEARCH; v. 19, n. 4, p. 183-191, DEC 1 2021.
Web of Science Citations: 0
Abstract

Prostate cancer is the second most common neoplasm among men, with a high mortality rate in advanced stages. Poly (ADP-ribose) polymerase (PARP) plays an important role in repair to DNA damage, being associated with resistance to tumor cell death. Conversely, Caspase-3 is a crucial mediator of programmed cell death, being highly expressed in apoptotic cells.The aim of the present study was to characterize the expression of PARP and Caspase-3 by immunohistochemistry in patients with advanced prostate cancer. PARP and Caspase-3 were independently correlated to patients' evolution, in accordance with the classification of prognostic groups.The increase in PARP expression was positively correlated with tumor patients with poor prognosis (P < 0.0001). In contrast, a decrease in Caspase-3 expression was identified in patients with poor prognosis, when compared with prostate cancer patients with good prognosis (P = 0.0007). Numerically, 92.3% of patients previously classified with poor prognosis showed higher PARP expression, while 93.75% of patients previously classified with good prognosis showed higher levels of Caspase-3.We conclude that PARP and Caspase-3 are potential prognostic markers for prostate cancer patients with different prognosis. (AU)

FAPESP's process: 19/11381-1 - Immunohistochemistry evaluation of PARP and caspase-3 as prognostic markers in prostate cancer
Grantee:Vitoria Acar
Support Opportunities: Scholarships in Brazil - Scientific Initiation